Tarsus Pharmaceuticals (NASDAQ:TARS) vs. Tilray Brands (NASDAQ:TLRY) Head-To-Head Survey

Tilray Brands (NASDAQ:TLRY) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Valuation & Earnings

This table compares Tilray Brands and Tarsus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45 million	0.67	-$121.40 million	($1.08)	-4.19
Tarsus Pharmaceuticals	$451.36 million	8.09	-$66.42 million	($1.09)	-76.34

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tilray Brands and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Insider and Institutional Ownership

9.3% of Tilray Brands shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Tilray Brands has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Tilray Brands and Tarsus Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1	3	2	1	2.43
Tarsus Pharmaceuticals	1	2	4	2	2.78

Tilray Brands presently has a consensus target price of $8.00, suggesting a potential upside of 76.60%. Tarsus Pharmaceuticals has a consensus target price of $90.50, suggesting a potential upside of 8.76%. Given Tilray Brands’ higher probable upside, equities research analysts plainly believe Tilray Brands is more favorable than Tarsus Pharmaceuticals.

Summary

Tarsus Pharmaceuticals beats Tilray Brands on 8 of the 15 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.